Alex from LDN Now, a resourceful LDN group from the UK, has written a wonderful, clear account of Mary Boyle Bradley's recent interview with Dr. Zagon.
Here's an excerpt:
As I understand it, the primary effect of the low dose naltrexone (LDN) protocol, which is more accurately termed intermittent opiate blockade, is the temporary blocking of opiate receptors. Opiate receptors are proteins found on the surface of the body’s cells, including immune system cells. Both endogenous (pentapeptide endorphins) and exogenous (opiate drugs) bind to and activate this receptor. As an opiate antagonist, naltrexone blocks the opiate receptor.
This causes the body to respond by producing more endorphins in an attempt to remedy the unavailability of the endorphin receptors. In addition, this stimulates the production of more endorphin receptors, which, in turn, increases the production of endorphin pentapeptides, including met-enkephalins, leu-enkephalins, and endorphins.
One of the issues LDN addresses is the low levels of endorphin receptor seen in some disease states. This presumably leads directly to low endorphin levels in the body. Low endorphin levels are associated with various autoimmune diseases and malignancies.
Link to the Andrew's Complete Review
Link to the Mary's Blog of the Dr. Zagon Interview
Both the blog and Andrew's summary are excellent sources of information.
Soon, I'll add the link to the blog with the June 30th interview Mary conducted with Sammy and me.